Materiały źródłowe

• #1 Predicting survival in malignant pleural mesothelioma using routine clinical and laboratory characteristics

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7797245/

  The prognosis of malignant pleural mesothelioma (MPM) is poor, with a median survival of 812 months. […] The ability to predict prognosis in MPM would help clinicians to make informed decisions regarding treatment and identify appropriate research opportunities for patients. […] Risk of death at 6 months in patients with a confirmed diagnosis of MPM can be predicted using variables readily available in clinical practice. […] The risk prediction model we have developed may be used to influence treatment decisions in patients with MPM. […] The prognosis of MPM is generally regarded as poor, with a median survival of between 8 and 12 months. […] The ability to predict prognosis in MPM would help clinicians to make informed decisions regarding treatment, tailored to individual patients, such as early specialist palliative care.

• #2 Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study | Thorax

  https://thorax.bmj.com/content/77/12/1260

  Malignant mesothelioma (MM) is an aggressive cancer that primarily arises from the pleura (MPM) or peritoneum (MPeM), mostly due to asbestos exposure. […] MPM prognosis is very poor, with a median overall survival (OS) of approximately 1 year when treated with chemotherapy. […] Recently, combination checkpoint inhibition therapy, consisting of nivolumab (anti-programmed death-ligand 1 (PD-1)) and ipilimumab (anti-cytotoxic T lymphocyte-associated protein 4 (CTLA4)), has been shown to increase OS in patients with MPM compared with standard first-line chemotherapy (median OS 18.1 months vs 14.1 months). […] For malignant peritoneal mesothelioma (MPeM), the median OS is about 6 months. […] The median overall survival improved from 7.3 (1993-2003) to 8.9 (2004-2011) and 9.3 months from 2012 to 2018 (p<0.001).

• #3 Prognosis and prognostic factors of patients with mesothelioma: a population-based study | British Journal of Cancer

  https://www.nature.com/articles/bjc2012245

  It is important to regularly update survival estimates of patients with malignant mesothelioma as prognosis may vary according to epidemiologic factors and diagnostic and therapeutic management. […] About 50% of the patients were 70 years or older at diagnosis and the median latency time since start of asbestos exposure was 49 years. One year after diagnosis, 47% of the patients were alive, 20% after 2 years and 15% after 3 years. Prognostic variables independently associated with worse survival were: older age (HR=1.04 per year 95% CI (1.03-1.06)), sarcomatoid subtype (HR=2.45 95% CI (2.06-2.90)) and non-pleural localisation (HR=1.67 95% CI (1.26-2.22)). […] Survival of patients with malignant mesothelioma is still limited and depends highly on patient age, mesothelioma subtype and localisation.

• #4 Prognosis and prognostic factors of patients with mesothelioma: a population-based study

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3389430/

  It is important to regularly update survival estimates of patients with malignant mesothelioma as prognosis may vary according to epidemiologic factors and diagnostic and therapeutic management. […] About 50% of the patients were 70 years or older at diagnosis and the median latency time since start of asbestos exposure was 49 years. One year after diagnosis, 47% of the patients were alive, 20% after 2 years and 15% after 3 years. Prognostic variables independently associated with worse survival were: older age (HR=1.04 per year 95% CI (1.031.06)), sarcomatoid subtype (HR=2.45 95% CI (2.062.90)) and non-pleural localisation (HR=1.67 95% CI (1.262.22)). […] Survival of patients with malignant mesothelioma is still limited and depends highly on patient age, mesothelioma subtype and localisation.

• #5 Mesothelioma Prognosis: Factors & Improving Prognosis of Mesothelioma

  https://www.asbestos.com/mesothelioma/prognosis/

  The key factors in a patients mesothelioma prognosis are the tumors origin, cell type, and stage at diagnosis. General health and other personal factors also affect the response to treatment. […] Patients diagnosed in the early stages have the best prognosis. […] The major or No. 1 factor that influences a patients prognosis is the amount of tumor that is visible at the time of diagnosis. […] Choosing mesothelioma treatment is the best way to improve a patients prognosis. Long-term survivors often undergo surgery, chemotherapy and radiation. […] Mesothelioma treatment can partly remit the cancer. This means a 50% reduction in tumor size. Full remission is having no signs or symptoms of active cancer, and it is rare with mesothelioma. Partial remission is more common. Patients may live for years in partial remission.

• #5 Mesothelioma Prognosis: Factors & Improving Prognosis of Mesothelioma

  https://www.asbestos.com/mesothelioma/prognosis/

  The prognosis for mesothelioma is often poor, but treatment can extend survival and improve prognosis. On average, patients live 12 to 21 months after diagnosis, and approximately 14% survive five years or longer. Prognosis depends on the cancer stage, patient’s health and treatment. […] The prognosis for mesothelioma, the likely course of the disease, is poor. Most mesothelioma patients live 1 to 2 years with treatment. Without it, they live 6 to 8 months. But some patients have defied the odds and lived more than 10 years. A mesothelioma prognosis is both individual and based on the outcomes of other patients. […] Survival rate, life expectancy, and mortality statistics affect prognosis. But every mesothelioma survivor is unique. […] Choosing mesothelioma treatment can improve the prognosis. Ongoing cancer treatment can help keep mesothelioma under control. Some patients live more than a decade after therapy.

• #6 Improving Mesothelioma Prognosis | Factors & Treatments

  https://www.mesothelioma.com/mesothelioma/prognosis/

  Stage 3 mesothelioma patients have an average life expectancy of 16 months or longer. […] Stage 4 mesothelioma patients have an average life expectancy of 12 months or longer. […] Different factors may affect a patient’s prognosis. […] The types of cells that make up a mesothelioma tumor influence prognosis: Epithelioid mesothelioma typically has the best prognosis. […] Nutrition plays an important role in a patient’s cancer prognosis. […] Some demographic factors that affect prognosis cannot be controlled. […] A patient’s health may have an impact on their prognosis. […] Some location factors may have an effect on mesothelioma prognosis. […] Some mesothelioma patients have achieved remission and long-term survival. […] Mesothelioma prognosis can be improved.

• #7

  https://link.springer.com/article/10.1007/s13665-013-0045-1

  The prognosis for patients with malignant pleural mesothelioma (MPM) is generally regarded as poor, although rare cases of long-term survivors are recognised. […] Population studies consistently confirm non-epithelioid histology, advanced age, and male gender as independent risk factors for poor outcome of MPM. […] The baseline serum neutrophil-to-lymphocyte ratio could also provide prognostic information. […] Modern metabolic imaging techniques, for example PET/CT, can indicate prognosis by use of baseline total glycolytic volumes (TGV). […] In summary, when a population-based approach is used to establish prognostic data, increased age, non-epithelioid histology, and male gender are the most consistently reported factors associated with poor outcome, with anatomical site (pleural/non-pleural) likely to be important.

• #8 Mesothelioma Life Expectancy: Key Factors and Life Span

  https://www.asbestos.com/mesothelioma/life-expectancy/

  People with early-stage mesothelioma tend to live for 19 to 21 months. Mesothelioma life expectancy is 21 months at stage 1, 19 at stage 2, 16 at stage 3 and 12 at stage 4. […] Tumor cell type affects mesothelioma life expectancy. This is because your cell type impacts which treatment is best for you. Epithelial tumors are linked to a higher life expectancy. […] Age, gender and overall health can all affect mesothelioma life expectancy. Older patients, men, and those with co-existing conditions live shorter lives. In contrast, women and healthier people tend to live longer. […] Treatment for mesothelioma can extend life expectancy several years for most patients. Stage 4 mesothelioma life expectancy is about 1 year with treatment. […] Pleural mesothelioma life expectancy without treatment is about 6 to 8 months. Peritoneal mesothelioma, untreated, has a life expectancy of about 6 months. […] Life expectancy after a mesothelioma diagnosis varies. It depends on the type, stage and treatment plan. Early detection and access to expert care can improve survival rates. In some cases, patients lived more than 5 years with aggressive treatment.

• #8 Mesothelioma Life Expectancy: Key Factors and Life Span

  https://www.asbestos.com/mesothelioma/life-expectancy/

  Mesothelioma life expectancy varies depending on treatment and individual factors. With treatment, patients typically live 12 to 21 months after diagnosis. Patients without treatment have a life expectancy of 6 to 8 months. Adopting healthy habits and new treatments may extend life expectancy. […] Oncologists often find it hard to give patients a precise life expectancy. Many factors can affect how long you live with mesothelioma. An early diagnosis, for example, can improve your mesothelioma life expectancy. […] Several factors affect mesothelioma life expectancy. These include the stage at diagnosis, tumor location, cell type and the patients health. Coexisting conditions play an important role. […] If you’ve had asbestos exposure, tell your doctor. Report any new or worsening symptoms. People who were exposed to asbestos should be watched closely. It can help lead to an earlier diagnosis. An early diagnosis may mean people can qualify to try more therapies.

• #9 Predicting survival in malignant pleural mesothelioma using routine clinical and laboratory characteristics

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7797245/

  The aim of this study was to identify clinical and pathological characteristics gathered during routine care, including demographic and clinical information, to predict risk of death in an unselected group of patients with MPM. […] The multivariate results suggest that the predictor variables of age (HR 1.31, 95%CI 1.09 to 1.56), smoking status (current smoker HR 3.42, 95%CI 1.11 to 4.20), chest pain (HR 2.14, 95%CI 1.23 to 3.72), weight loss (HR 2.13, 95%CI 1.18 to 3.72), platelet count (HR 1.05, 95%CI 1.00 to 1.10), urea (HR 2.73, 95%CI 1.31 to 5.69) and adjusted calcium (HR 1.47, 95%CI 1.10 to 1.94) are independently associated with patient survival. […] In summary, we have developed a model to predict risk of death at 6 months in patients with a confirmed diagnosis of MPM using variables readily available in clinical practice, derived from an unselected population at diagnosis.

• #10

  https://link.springer.com/article/10.1007/s13665-013-0045-1

  One of the strongest predictors of survival in mesothelioma is histological subtype: many groups, all reaching similar conclusions, have reported this. […] Epithelioid mesothelioma has slower progression than the sarcomatoid variant. […] A grading system based on these results was used to stratify clinicopathological factors by nuclear grade; it revealed statistical association of higher grade nuclear atypia and mitotic count with lymphatic and vascular invasion, and tumour, nodal, and overall stage. […] Angiogenesis is essential for tumour growth beyond a few millimetres. […] Increased MVD levels are an independent prognostic factor for poor MPM survival in this surgical group. […] Aside from the clear utility of immunohistochemical markers in diagnosis of MPM, at present there is no immunostain, or combination of immunostains, providing reliable prognostic information for clinicians.

• #11 Mesothelioma Prognosis: Factors, Treatments & Survival Rates

  https://www.mesotheliomaguide.com/prognosis/

  The prognosis for stage 3 pleural mesothelioma is approximately 15 months of survival. The prognosis for stage 4 pleural mesothelioma is usually 11-12 months. […] The prognosis for peritoneal mesothelioma is survival of 2-3 years with treatment. Cytoreductive surgery and HIPEC gives patients an average life expectancy of 3-5 years. […] The average survival for biphasic mesothelioma is 13 months. […] Sarcomatoid mesothelioma has an average survival of 8-12 months, depending on the location of the disease, but the average prognosis is improving. […] The patients stage of mesothelioma is another contributing factor for their prognosis. People in stage 1 and 2 have a better outlook than people in later stages. […] The prognosis depends on the age and health of the patient, particularly if they can handle living with one lung. The average survival after this surgery is close to 20 months, so the prognosis is a little better than the average.

• #12 Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study | Modern Pathology

  https://www.nature.com/articles/modpathol2017170

  A recently described nuclear grading system predicted survival in patients with epithelioid malignant pleural mesothelioma. […] The overall survival was 16 months, and correlated independently with age (P=0.006), sex (0.015), necrosis (0.030), mitotic count (0.001), nuclear atypia (0.009), nuclear grade (0.0001), and mitosis and necrosis score (0.0001). […] The addition of necrosis to nuclear grade further stratified overall survival, allowing classification of epithelioid malignant pleural mesothelioma into four distinct prognostic groups: nuclear grade I tumors without necrosis (29 months), nuclear grade I tumors with necrosis and grade II tumors without necrosis (16 months), nuclear grade II tumors with necrosis (10 months) and nuclear grade III tumors (8 months). […] This study confirms that nuclear grade predicts survival in epithelioid malignant pleural mesothelioma, identifies necrosis as factor that further stratifies overall survival, and validates the grading system across multiple institutions and among both biopsy and resection specimens.

• #13 Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study | Modern Pathology

  https://www.nature.com/articles/modpathol2017170

  Patients with tumors with necrosis had a significantly lower median overall survival than those without (10 vs 19 months, HR 1.85, CI: 1.57-2.17, P=0.0001). […] Overall, survival decreased significantly from patients with nuclear grade I tumors without necrosis (29 months) to those with nuclear grade I tumors with necrosis or nuclear grade II tumors without necrosis (16 months) to nuclear grade II tumors with necrosis (10 months), and nuclear grade III tumors (8 months). […] In conclusion, nuclear grade and necrosis predict overall survival in epithelioid malignant pleural mesothelioma. The addition of necrosis to nuclear grade allows for greater separation of overall survival.

• #14 Malignant peritoneal mesothelioma: a review – Broeckx – Translational Lung Cancer Research

  https://tlcr.amegroups.org/article/view/24639/html

  Malignant peritoneal mesothelioma (MPM) is a very rare malignancy of the peritoneum and has a poor prognosis. […] The gold standard treatment remains cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). […] The main determinant of outcome in combined CRS and HIPEC is the completeness of surgical cytoreduction. […] Without treatment, median survival has been reported from less than 5 months to up to 12 months from the time of diagnosis. […] According to the RENAPE study, overall survival was better in CC-0 (i.e., optimal CRS) patients with an epithelioid histological subtype in the two drugs group versus the one-drug group. […] A meta-analysis of 20 studies, that included 1,047 patients with MPM treated with CRS-HIPEC, showed a 5-year survival of 42% in the 67% of patients that achieved a complete or near complete cytoreduction prior to HIPEC.

• #15 Improving Mesothelioma Prognosis | Factors & Treatments

  https://www.mesothelioma.com/mesothelioma/prognosis/

  In studies, patients who had mesothelioma surgery as part of a multimodal treatment plan lived about 2 – 6 years. […] The average prognosis for mesothelioma ranges from 18 to 31 months with treatment. […] Patients typically have the best mesothelioma prognosis after multimodal treatments. […] Some peritoneal mesothelioma patients had more than six years life expectancy after multimodal treatments. […] The type of mesothelioma, or where the cancer develops, affects the prognosis of the disease. […] The prognosis for peritoneal mesothelioma is about 2 – 6 years, depending on a number of factors. […] Stage has a strong relationship with prognosis. […] Stage 1 mesothelioma patients have an average life expectancy of 21 months or longer. […] Stage 2 mesothelioma patients have an average life expectancy of 19 months or longer.

• #16

  https://link.springer.com/article/10.1007/s13665-013-0045-1

  The reports summarised above provide interesting information, with the potential to advance our understanding of the genetics of tumour biology and prognosis in MPM, but none yet delivers markers or quantitative data that have direct prognostic relevance for clinicians. […] High levels of serum VEGF (460 pg mL1) were associated with poor survival. […] A high ratio suggests greater systemic inflammation. […] Epithelioid histology (HR 2.0, 95 % CI 1.32.9) and NLR of five or below (HR 2.7, 95 % CI 1.83.9) were independently predictive of survival. […] Baseline mesothelin levels 5 nmol L1 were a significant negative prognostic indicator (HR 2.25, 95 % CI 1.24.21) and correlated with tumour stage and volume. […] Overall, the prognosis for mesothelioma is poor. […] There remains a need for identification of validated, clinically relevant prognostic factors that can be generalised to the wider population with mesothelioma.

• #17 Predicting survival for patients with mesothelioma: development of the PLACE prognostic model | BMC Cancer | Full Text

  https://bmccancer.biomedcentral.com/articles/10.1186/s12885-023-11180-y

  The overall survival of patients with mesothelioma is poor and heterogeneous. […] We sought to investigate predictors of survival in malignant pleural mesothelioma and develop prognostic prediction models. […] The survival rate of patients in the high-risk group was significantly lower than that in the low-risk group (hazard ratio [HR], 3.878; 95% confidence interval [CI], 2.2266.755; P0.001). […] We developed a simple, clinically relevant prognostic prediction model for PLACE by evaluating five variables routinely tested at the time of diagnosis. […] The predictive model can differentiate patients of Chinese ethnicity into different risk groups and further guide prognosis. […] Therefore, it is necessary to analyse the independent predictive factors related to the prognosis of patients with mesothelioma, and further establish a prognosis prediction model to predict the possible survival time of patients.

• #18 Predicting survival for patients with mesothelioma: development of the PLACE prognostic model | BMC Cancer | Full Text

  https://bmccancer.biomedcentral.com/articles/10.1186/s12885-023-11180-y

  According to this model, mesothelioma patients were divided into two distinct prognostic risk groups. Prognosis of patients differs significantly between high and low risk groups. […] The survival rate of the high-risk group was significantly lower than that of the low-risk group (HR: 3.878; 95% CI: 2.2266.755; P0.001). […] The survival rate of the high-risk group was significantly lower than that of the low-risk group (HR: 3.574; 95% CI: 1.06412.001; P=0.039).

• #19 Deep learning-based classification of mesothelioma improves prediction of patient outcome. – Document – Gale OneFile: Health and Medicine

  https://go.gale.com/ps/i.do?id=GALE%7CA602136556&sid=googleScholar&v=2.1&it=r&linkaccess=abs&issn=10788956&p=HRCA&sw=w

  Malignant mesothelioma (MM) is an aggressive cancer primarily diagnosed on the basis of histological criteria. […] Here we have developed a new approach–based on deep convolutional neural networks–called MesoNet to accurately predict the overall survival of mesothelioma patients from whole-slide digitized images, without any pathologist-provided locally annotated regions. […] We also demonstrated that the model was more accurate in predicting patient survival than using current pathology practices. […] Strikingly, we found that these regions are mainly located in the stroma and are histological features associated with inflammation, cellular diversity and vacuolization. […] Deep convolutional neural networks predict survival of mesothelioma patients and identify histological features associated with outcome that transcend current histological classifications.

• #20 Improving Mesothelioma Prognosis | Factors & Treatments

  https://www.mesothelioma.com/mesothelioma/prognosis/

  The most important thing a patient can do to improve their prognosis may be to get treatment. Research shows that patients who undergo treatment have a better prognosis than those who do not: Mesothelioma prognosis without treatment: 6 months […] Mesothelioma prognosis with some form of treatment: 18 – 31 months. […] Treatment is the best way to improve the prognosis for mesothelioma cancer. Some treatments have proven to be more effective in improving prognosis than others. […] Research shows patients who receive a multimodal treatment live about 2 – 6 years. […] Studies show pleural mesothelioma patients treated with chemotherapy live about 14 months after diagnosis. […] In studies, the prognosis for patients receiving immunotherapy treatments ranges from 18 to 24 months. […] Mesothelioma patients may see improved prognosis following radiation therapy.

• #21 Malignant peritoneal mesothelioma: a review – Broeckx – Translational Lung Cancer Research

  https://tlcr.amegroups.org/article/view/24639/html

  The efficacy of pemetrexed alone or in combination with cisplatin for MPM was reported in two studies, which showed that the median survival for pemetrexed alone was 8.7 months compared to 13.1 months for patients who received cisplatin as well. […] These results and the general lack of good responses to systemic therapy suggest that upfront CRS and HIPEC are preferable. […] The addition of chemotherapy to CRS provided a short-time survival improvement of 1 year only and was similar whether given in the neoadjuvant setting. […] Ongoing immunotherapy trials will offer a possible new treatment.

• #22 Mesothelioma Prognosis | Survival Rates & How to Improve

  https://www.mesotheliomahope.com/mesothelioma/prognosis/

  Average Prognosis for Mesothelioma Cancer: With Treatment: 12-21 months. Without Treatment: 4-12 months. […] A prognosis is a predicted health outcome for an individual patient. A mesothelioma doctor can provide a prognosis based on your cancer’s location, cell type, stage, and other factors. […] The average prognosis for mesothelioma cancer is 12-21 months with treatment. The average mesothelioma prognosis without treatment is 4-12 months. […] Many of the patients we’ve helped have become 15+ year survivors after being told they had a few months to live. […] Mesothelioma treatment and prognosis are closely linked. Finding a mesothelioma specialist who can create a custom treatment plan is the best way to improve your prognosis. […] Depending on your health and other factors, your oncologist (cancer doctor) may recommend a combination of treatments, called multimodal therapy. Multimodal treatment can improve your mesothelioma prognosis by targeting different aspects of the disease.

• #23 Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study | Thorax

  https://thorax.bmj.com/content/77/12/1260

  The majority of patients do not receive treatment though and prognosis is still poor. […] While treatment advances have led to somewhat better survival, prognosis is still dismal. […] The majority of patients, however, did not undergo antitumour treatment. […] The current cohort, the use and thus the impact of immunotherapy and targeted therapy were minimal, with less than 1% of patients treated with either modality. […] Nonetheless, novel treatment options are still urgently required to improve survival in patients. […] This study shows that MM incidence has reached a peak in the Netherlands around 2010, following the national ban on asbestos in 1993. […] In this period, survival improved slightly, but the prognosis is still poor.

• #24 Mesothelioma Prognosis: Factors & Improving Prognosis of Mesothelioma

  https://www.asbestos.com/mesothelioma/prognosis/

  You can choose to be proactive and take steps to improve your mesothelioma prognosis. Although you cant change your age or cancer stage, you can choose to seek treatment and make healthy lifestyle choices. […] While mesothelioma is considered terminal, its not always fatal. Patients have outlived their prognosis by more than a decade.

• #25 Mesothelioma Prognosis | Survival Rates & How to Improve

  https://www.mesotheliomahope.com/mesothelioma/prognosis/

  Making healthy lifestyle choices can help your body recover from mesothelioma treatment and improve your overall well-being. Both of these can have a positive effect on your mesothelioma prognosis. […] You may also be able to improve your prognosis by joining mesothelioma clinical trials to access new and emerging treatments. […] The type of mesothelioma you have will impact your prognosis. […] Malignant pleural mesothelioma develops in the lining of the lung and has an average prognosis of 8-22 months. […] Your age, overall health, and cell type also impact your prognosis. […] Malignant peritoneal mesothelioma develops in the lining of the abdomen and has an average prognosis of 53 months. […] The average pericardial mesothelioma prognosis is 2-6 months because of the cancer’s closeness to the heart.

• #26 Mesothelioma Prognosis | Survival Rates & How to Improve

  https://www.mesotheliomahope.com/mesothelioma/prognosis/

  The average prognosis for mesothelioma is not as favorable as other cancers, with patients living for 15 months on average. […] The median overall life expectancy of mesothelioma patients is 15 months. However, there are mesothelioma survivors who have outlived their prognosis by more than 20 years. […] While the overall prognosis for mesothelioma is poor, advancements in medicine and treatments are offering new hope for patients and their families. Early detection and treatment can make a significant difference in your mesothelioma prognosis. […] Understanding the stage of your mesothelioma is an important step in determining your prognosis and finding the best treatments. […] The chart below lists the average pleural mesothelioma prognosis for each stage and the percentage of patients still alive after 2 years (also known as the mesothelioma survival rate).

Zobacz więcej